{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:54:58Z","timestamp":1762955698441},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Daval International"},{"name":"EULAR Orphan Diseases Programme"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1252-x","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T13:03:25Z","timestamp":1488891805000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multiplex serum protein analysis reveals potential mechanisms and markers of response to hyperimmune caprine serum in systemic sclerosis"],"prefix":"10.1186","volume":"19","author":[{"given":"Niamh","family":"Quillinan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina E. N.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Youl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Vernes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deirdre","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Haq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,7]]},"reference":[{"issue":"10","key":"1252_CR1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jocn.2006.03.009","volume":"13","author":"R Mackenzie","year":"2006","unstructured":"Mackenzie R, Kiernan M, McKenzie D, Youl BD. Hyperimmune goat serum for amyotrophic lateral sclerosis. J Clin Neurosci. 2006;13(10):1033\u20136.","journal-title":"J Clin Neurosci"},{"issue":"11","key":"1252_CR2","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.jocn.2009.03.019","volume":"16","author":"RA Mackenzie","year":"2009","unstructured":"Mackenzie RA. Follow-up study of hyper-immune goat serum (Aimspro) for amyotrophic lateral sclerosis (ALS). J Clin Neurosci. 2009;16(11):1508\u20139.","journal-title":"J Clin Neurosci"},{"key":"1252_CR3","volume-title":"Goat serum product AIMSPRO\u00ae shows promise as an effective treatment in CIDP","author":"BD Youl","year":"2004","unstructured":"Youl BD, Ginsberg L. Goat serum product AIMSPRO\u00ae shows promise as an effective treatment in CIDP. London: BSCN meeting, National Hospital; 2004."},{"key":"1252_CR4","first-page":"S110","volume":"238","author":"BD Youl","year":"2005","unstructured":"Youl BD, Crum J. Clinical improvement in Krabbe\u2019s disease case treated with hyperimmune goat serum product AIMSPRO\u00ae. J Neurol Sci. 2005;238:S110.","journal-title":"J Neurol Sci"},{"key":"1252_CR5","first-page":"S177","volume":"238","author":"BD Youl","year":"2005","unstructured":"Youl BD, Angus-Leppan H, Hussein N, Brooman I, Fitzsimons RB. Rapid and sustained response to hyperimmune goat serum product in a patient with Myaesthenia Gravis. J Neurol Sci. 2005;238:S177.","journal-title":"J Neurol Sci"},{"key":"1252_CR6","first-page":"S238","volume":"238","author":"CEG Moore","year":"2005","unstructured":"Moore CEG, Hannan R, McIntosh D. In vivo, human peripheral nerve strength duration time constant changes with AIMSPRO\u00ae implicate altered sodium channel function as a putative mechanism of action. J Neurol Sci. 2005;238:S238.","journal-title":"J Neurol Sci"},{"key":"1252_CR7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/B978-0-7216-9491-7.50008-9","volume-title":"Peripheral Neuropathy","author":"MC Kiernan","year":"2005","unstructured":"Kiernan MC, Burke D, Bostock H. Nerve excitability measures: biophysical basis and use in investigation of peripheral nerve disease use in investigation of peripheral nerve disease. In: Dyck PJ, Thomas PK, editors. Peripheral Neuropathy. 4th ed. Philadelphia: Elsevier Saunders; 2005. p. 113\u201329.","edition":"4"},{"key":"1252_CR8","first-page":"1326","volume":"76","author":"G Burke","year":"2005","unstructured":"Burke G, Cavey A, Matthews P, Palace J. The evaluation of a novel \u2018goat serum\u2019 (AIMSPRO\u00ae) in multiple sclerosis. J Neurol Neurosurg Psychiatr. 2005;76:1326.","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"1252_CR9","first-page":"615","volume":"76","author":"BD Youl","year":"2004","unstructured":"Youl BD, White SDT, McIntosh D, Cadogan M, Dalgleish AG, Ginsberg L. Hyperimmune serum reverses conduction block in demyelinated human optic nerve and peripheral nerve fibres. J Neurol Neurosurg Psychiatr. 2004;76:615.","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"1252_CR10","first-page":"S169","volume":"238","author":"BD Youl","year":"2005","unstructured":"Youl BD, Orrell R. Goat serum product AIMSPRO\u00ae produces sustained improvement in muscle power in a patient with fascioscapulohumeral dystrophy. J Neurol Sci. 2005;238:S169.","journal-title":"J Neurol Sci"},{"issue":"1","key":"1252_CR11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/annrheumdis-2013-203674","volume":"73","author":"NP Quillinan","year":"2014","unstructured":"Quillinan NP, McIntosh D, Vernes J, Haq S, Denton CP. Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial. Ann Rheum Dis. 2014;73(1):56\u201361.","journal-title":"Ann Rheum Dis"},{"issue":"2 Suppl 71","key":"1252_CR12","first-page":"S97","volume":"30","author":"L Chung","year":"2012","unstructured":"Chung L, Denton CP, Distler O, Furst DE, Khanna D, Merkel PA. Clinical trial design in scleroderma: where are we and where do we go next? Clin Exp Rheumatol. 2012;30(2 Suppl 71):S97\u2013102.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1252_CR13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/rheumatology\/keu288","volume":"54","author":"D Khanna","year":"2015","unstructured":"Khanna D, Furst DE, Allanore Y, Bae S, Bodukam V, Clements PJ, et al. Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. Rheumatology (Oxford). 2015;54(1):144\u201351.","journal-title":"Rheumatology (Oxford)"},{"key":"1252_CR14","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/annrheumdis-2014-205226","volume":"74","author":"B Maurer","year":"2015","unstructured":"Maurer B, Graf N, Michel BA, M\u00fcller-Ladner U, Czirj\u00e1k L, Denton CP, Tyndall A, Metzig C, Lanius V, Khanna D, Distler O. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis. 2015;74:1124\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1252_CR15","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1183\/09031936.00028209","volume":"34","author":"P Beirne","year":"2009","unstructured":"Beirne P, Pantelidis P, Charles P, Wells AU, Abraham DJ, Denton CP, et al. Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis. Eur Respir J. 2009;34(6):1376\u201382.","journal-title":"Eur Respir J"},{"issue":"6","key":"1252_CR16","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10875-014-0037-0","volume":"34","author":"S Vettori","year":"2014","unstructured":"Vettori S, Cuomo G, Iudici M, D\u2019Abrosca V, Giacco V, Barra G, et al. Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. J Clin Immunol. 2014;34(6):663\u20138.","journal-title":"J Clin Immunol"},{"issue":"8","key":"1252_CR17","doi-asserted-by":"crossref","first-page":"e12106","DOI":"10.1371\/journal.pone.0012106","volume":"5","author":"SA Pendergrass","year":"2010","unstructured":"Pendergrass SA, Hayes E, Farina G, Lemaire R, Farber HW, Whitfield ML, et al. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One. 2010;5(8):e12106.","journal-title":"PLoS One"},{"issue":"11","key":"1252_CR18","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1002\/art.39287","volume":"67","author":"LM Rice","year":"2015","unstructured":"Rice LM, Ziemek J, Stratton EA, McLaughlin SR, Padilla CM, Mathes AL, et al. A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 2015;67(11):3004\u201315.","journal-title":"Arthritis Rheumatol"},{"key":"1252_CR19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13075-015-0669-3","volume":"17","author":"EF Chakravarty","year":"2015","unstructured":"Chakravarty EF, Martyanov V, Fiorentino D, Wood TA, Haddon DJ, Jarrell JA, et al. Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. Arthritis Res Ther. 2015;17:159.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1252_CR20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/annrheumdis-2012-202843","volume":"73","author":"G Abignano","year":"2014","unstructured":"Abignano G, Cuomo G, Buch MH, Rosenberg WM, Valentini G, Emery P, et al. The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. Ann Rheum Dis. 2014;73(2):420\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1252_CR21","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1021\/np900360m","volume":"72","author":"JD Thacker","year":"2009","unstructured":"Thacker JD, Brown MA, Rest RF, Purohit M, Sassi-Gaha S, Artlett CM. 1-Peptidyl-2-arachidonoyl-3-stearoyl-sn-glyceride: an immunologically active lipopeptide from goat serum (Capra hircus) is an endogenous damage-associated molecular pattern. J Nat Prod. 2009;72(11):1993\u20139.","journal-title":"J Nat Prod"},{"issue":"2","key":"1252_CR22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3899\/jrheum.140833","volume":"42","author":"CL Poelman","year":"2015","unstructured":"Poelman CL, Hummers LK, Wigley FM, Anderson C, Boin F, Shah AA. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. J Rheumatol. 2015;42(2):236\u201342.","journal-title":"J Rheumatol"},{"issue":"2 Suppl 76","key":"1252_CR23","first-page":"151","volume":"31","author":"K Takehara","year":"2013","unstructured":"Takehara K, Ihn H, Sato S. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol. 2013;31(2 Suppl 76):151\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1252_CR24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/rheumatology\/kev318","volume":"55","author":"J Raja","year":"2016","unstructured":"Raja J, Nihtyanova SI, Murray CD, Denton CP, Ong VH. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology (Oxford). 2016;55(1):115\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"4 Suppl 91","key":"1252_CR25","first-page":"S168","volume":"33","author":"KE Clark","year":"2015","unstructured":"Clark KE, Etomi O, Denton CP, Ong VH, Murray CD. Intravenous immunogobulin therapy for severe gastrointestinal involvement in systemic sclerosis. Clin Exp Rheumatol. 2015;33(4 Suppl 91):S168\u201370.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"1252_CR26","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/jgm.899","volume":"8","author":"TH Lee","year":"2006","unstructured":"Lee TH, Jawan B, Chou WY, Lu CN, Wu CL, Kuo HM, et al. Alpha-melanocyte-stimulating hormone gene therapy reverses carbon tetrachloride induced liver fibrosis in mice. J Gene Med. 2006;8(6):764\u201372.","journal-title":"J Gene Med"},{"issue":"4","key":"1252_CR27","first-page":"628","volume":"46","author":"Z Zhang","year":"2012","unstructured":"Zhang Z, Ma J, Yao K, Yin J. Alpha-melanocyte stimulating hormone suppresses the proliferation of human tenon\u2019s capsule fibroblast proliferation induced by transforming growth factor beta 1. Mol Biol (Mosk). 2012;46(4):628\u201333.","journal-title":"Mol Biol (Mosk)"},{"issue":"11","key":"1252_CR28","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/exd.12250","volume":"22","author":"LF Luo","year":"2013","unstructured":"Luo LF, Shi Y, Zhou Q, Xu SZ, Lei TC. Insufficient expression of the melanocortin-1 receptor by human dermal fibroblasts contributes to excess collagen synthesis in keloid scars. Exp Dermatol. 2013;22(11):764\u20136.","journal-title":"Exp Dermatol"},{"issue":"8","key":"1252_CR29","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1074\/jbc.M312549200","volume":"279","author":"M Bohm","year":"2004","unstructured":"Bohm M, Raghunath M, Sunderkotter C, Schiller M, Stander S, Brzoska T, et al. Collagen metabolism is a novel target of the neuropeptide alpha-melanocyte-stimulating hormone. J Biol Chem. 2004;279(8):6959\u201366.","journal-title":"J Biol Chem"},{"issue":"11","key":"1252_CR30","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1210\/en.2005-0665","volume":"146","author":"M Bohm","year":"2005","unstructured":"Bohm M, Eickelmann M, Li Z, Schneider SW, Oji V, Diederichs S, et al. Detection of functionally active melanocortin receptors and evidence for an immunoregulatory activity of alpha-melanocyte-stimulating hormone in human dermal papilla cells. Endocrinology. 2005;146(11):4635\u201346.","journal-title":"Endocrinology"},{"issue":"2","key":"1252_CR31","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/art.24228","volume":"60","author":"A Kokot","year":"2009","unstructured":"Kokot A, Sindrilaru A, Schiller M, Sunderkotter C, Kerkhoff C, Eckes B, et al. alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma? Arthritis Rheum. 2009;60(2):592\u2013603.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1252_CR32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/exd.12409","volume":"23","author":"M Bohm","year":"2014","unstructured":"Bohm M, Stegemann A. Bleomycin-induced fibrosis in MC1 signalling-deficient C57BL\/6\u00a0J-Mc1r(e\/e) mice further supports a modulating role for melanocortins in collagen synthesis of the skin. Exp Dermatol. 2014;23(6):431\u20133.","journal-title":"Exp Dermatol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T12:05:16Z","timestamp":1498392316000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1252-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,7]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1252-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,7]]},"article-number":"45"}}